Octreotide sustained release - Midatech Pharma

Drug Profile

Octreotide sustained release - Midatech Pharma

Alternative Names: MTD-201; Q-Octreotide

Latest Information Update: 15 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Midatech
  • Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
  • Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acromegaly; Malignant carcinoid syndrome

Most Recent Events

  • 09 Jan 2018 Polish regulators approve the first-in-human trial for octreotide sustained release in European Union
  • 14 Jul 2016 Chemical structure information added
  • 18 May 2016 Midatech plans to file an IND for octreotide sustained release with the US FDA and initiate human bioequivalence studies in first half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top